Paolo Borghetti1, Marco Lorenzo Bonù2, Rachele Giubbolini3, Niccolo' Giaj Levra4, Rosario Mazzola4, Marco Perna5, Luca Visani5, Fiammetta Meacci5, Maria Taraborrelli6, Luca Triggiani1, Davide Franceschini7, Carlo Greco8, Alessio Bruni3, Stefano Maria Magrini1, Vieri Scotti5. 1. Department of Radiation Oncology, Istituto del Radio O. Alberti, Spedali Civili Hospital and Brescia University, Brescia, Italy. 2. Department of Radiation Oncology, Istituto del Radio O. Alberti, Spedali Civili Hospital and Brescia University, Brescia, Italy. marcolorenzo89.mlb@gmail.com. 3. Radiotherapy Unit, Oncology and Hematology Department, University Hospital of Modena, Modena, Italy. 4. Department of Radiation Oncology, Sacro Cuore Hospital, Negrar, Italy. 5. Department of Oncology Radiation Therapy Unit, Careggi University Hospital, Florence, Italy. 6. Radiotherapy Unit, SS Annunziata Hospital - G. D'annunzio University, Chieti, Italy. 7. Department of Radiotherapy and Radiosurgery, Humanitas Research Hospital and Cancer Center, Milan, Rozzano, Italy. 8. Departement of Radiation Oncology, Campus Bio-Medico University, Rome, Italy.
Abstract
PURPOSE: To investigate the role of radiotherapy (RT) in the management of EGFR- or ALK-mutated metastatic non-small cell lung cancer (NSCLC) treated with TKI. MATERIALS AND METHODS: Clinical data of 106 patients (pts) from five Institutions treated with RT concomitant to TKI were retrospectively revised. Overall survival (OS) and toxicities were analyzed as endpoints of the study. RESULTS: Median age of pts was 65 years. TKIs were given for EGFR (81%)- or ALK (19%)-mutated metastatic NSCLC. Stereotactic RT (SRT) was delivered to 49 pts (46%). Patients with four or less metastasis were defined as oligometastatic/oligoprogressive (OM/OP); sites of RT were brain, bone, lung or others in 46%, 27%, 14% and 13%, respectively. Median OS was 23 months. At univariate analysis SRT, ECOG PS 0-1, OM/OP disease, lung sites and a TKI duration longer than median favorably affected OS (all p < 0.001). Multivariate analysis confirmed SRT (HR 0.355, CI 95% 0.212-0.595; p < 0.001) and median duration of TKI > 14 months (HR 0.17, 95% CI 0.10-0.30; p < 0.001) as independent factors related to better OS. Toxicities were rare. CONCLUSIONS: SRT seems to positively affect OS with limited toxicity in selected patients.
PURPOSE: To investigate the role of radiotherapy (RT) in the management of EGFR- or ALK-mutated metastatic non-small cell lung cancer (NSCLC) treated with TKI. MATERIALS AND METHODS: Clinical data of 106 patients (pts) from five Institutions treated with RT concomitant to TKI were retrospectively revised. Overall survival (OS) and toxicities were analyzed as endpoints of the study. RESULTS: Median age of pts was 65 years. TKIs were given for EGFR (81%)- or ALK (19%)-mutated metastatic NSCLC. Stereotactic RT (SRT) was delivered to 49 pts (46%). Patients with four or less metastasis were defined as oligometastatic/oligoprogressive (OM/OP); sites of RT were brain, bone, lung or others in 46%, 27%, 14% and 13%, respectively. Median OS was 23 months. At univariate analysis SRT, ECOG PS 0-1, OM/OP disease, lung sites and a TKI duration longer than median favorably affected OS (all p < 0.001). Multivariate analysis confirmed SRT (HR 0.355, CI 95% 0.212-0.595; p < 0.001) and median duration of TKI > 14 months (HR 0.17, 95% CI 0.10-0.30; p < 0.001) as independent factors related to better OS. Toxicities were rare. CONCLUSIONS: SRT seems to positively affect OS with limited toxicity in selected patients.
Authors: Vincent Fallet; Lise Matton; Antoine Schernberg; Anthony Canellas; François H Cornelis; Jacques Cadranel Journal: Transl Lung Cancer Res Date: 2021-07
Authors: Yue Zhou; Fan Yu; Yang Zhao; Ya Zeng; Xi Yang; Li Chu; Xiao Chu; Yida Li; Liqing Zou; Tiantian Guo; Zhengfei Zhu; Jianjiao Ni Journal: Transl Lung Cancer Res Date: 2020-12
Authors: Ben Man Fei Cheung; Kin Sang Lau; Victor Ho Fun Lee; To Wai Leung; Feng-Ming Spring Kong; Mai Yee Luk; Kwok Keung Yuen Journal: Radiat Oncol J Date: 2021-10-26